KLOX Technologies to present innovative AC-1 biophotonic platform for acne treatment in New York City

Klox Technologies' President and CEO to pronounce conference entitled "The New Generation in Optical Dermatology and Tissue Repair"

MONTREAL, Sept. 10, 2013 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX") announced today that it will be presenting its AC-1 BioPhotonic system, an innovative and effective treatment for moderate to severe acne, at Rodman & Renshaw's 15th Annual Global Investment conference in New York City.  KLOX's President and CEO, Dr. Lise Hébert, will pronounce a conference entitled "The New Generation in Optical Dermatology and Tissue Repair".

Of the 140 million people worldwide who suffer from this chronic and often debilitating dermatological condition, over 20% suffer from moderate to severe forms of acne. The multi-billion dollar global acne market currently lacks non-systemic and non-invasive treatments with strong efficacy and good safety profiles; KLOX is confident that its system will be able to fill this significant void and with these strong results plans to introduce the system on the market as the Lumigel Cleanse™ and Lumiderm™ Light.

KLOX recently unveiled new AC-1 data from extension trial which demonstrates its system is poised to become leading acne treatment. These results provide further support that the system is a safe, highly effective, novel solution with long-lasting efficacy results.

DATEBOOK:

KLOX at Rodman & Renshaw's 15th Annual Global Investment conference - September 10^th, 2013, New York City

• The New Generation in Optical Dermatology and Tissue Repair
  
  Presenter: Dr. Lise Hébert, President and CEO, KLOX Technologies Inc.
  
  Tuesday, September 10^th - 9:35 AM / 10:00 AM (EDT), Millenium Broadway Hotel (Room 7.03, 7^th floor), New York City

ON TWITTER
KLOX Technologies corporate account: @KLOXTech
Rodman & Renshaw's 15th Annual Global Investment conference: @Rodman_2013

About KLOX Technologies: Leveraging light-based biophotonic technologies
www.kloxtechnologies.com/en/investor-relations

KLOX is a privately-owned company focused on the development and commercialization of a unique, non-invasive biophotonic technology using a primary device consisting of a multiple LED lighting system that interacts with an oxygen-rich gel containing light-trapping molecules. KLOX's cosmetics and medical devices are destined for the rapidly growing aesthetics, dermatological, tissue repair and dental markets.

SOURCE: KLOX Technologies Inc.

Roch Landriault
NATIONAL Public Relations
[phone]
[email protected]